Jacobs Levy Equity Management’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-37,646
| Closed | -$182K | – | 1199 |
|
|
2020
Q1 | $182K | Buy |
37,646
+13,717
| +57% | +$88.9K | ﹤0.01% | 901 |
|
|
2019
Q4 | $254K | Buy |
+23,929
| New | +$238K | ﹤0.01% | 894 |
|
|
2019
Q2 | – | Sell |
-29,864
| Closed | -$384K | – | 1076 |
|
|
2019
Q1 | $384K | Sell |
29,864
-15,549
| -34% | -$176K | 0.01% | 810 |
|
|
2018
Q4 | $431K | Buy |
+45,413
| New | +$589K | 0.01% | 758 |
|
|
2018
Q3 | – | Sell |
-30,656
| Closed | -$492K | – | 1112 |
|
|
2018
Q2 | $492K | Buy |
+30,656
| New | +$547K | 0.01% | 802 |
|
|
2018
Q1 | – | Sell |
-12,360
| Closed | -$193K | – | 1101 |
|
|
2017
Q4 | $193K | Buy |
+12,360
| New | +$165K | ﹤0.01% | 913 |
|
|
2017
Q2 | – | Sell |
-18,700
| Closed | -$160K | – | 1053 |
|
|
2017
Q1 | $160K | Sell |
18,700
-6,254
| -25% | -$57K | ﹤0.01% | 820 |
|
|
2016
Q4 | $267K | Sell |
24,954
-26,289
| -51% | -$318K | 0.01% | 788 |
|
|
2016
Q3 | $555K | Sell |
51,243
-4,611
| -8% | -$37.5K | 0.01% | 698 |
|
|
2016
Q2 | $378K | Buy |
55,854
+5,994
| +12% | +$37.8K | 0.01% | 830 |
|
|
2016
Q1 | $232K | Buy |
+49,860
| New | +$244K | ﹤0.01% | 937 |
|
|
2015
Q3 | – | Sell |
-13,400
| Closed | -$158K | – | 892 |
|
|
2015
Q2 | $158K | Buy |
+13,400
| New | +$186K | ﹤0.01% | 750 |
|
Jacobs Levy Equity Management's STML Position: Q2 2020 in Review
Jacobs Levy Equity Management sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 37,646 shares — an estimated $182K sold.
Jacobs Levy Equity Management first reported a position in STML in Q2 2015 and held it in 12 quarters. The position peaked at $555K in Q3 2016. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Jacobs Levy Equity Management reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Jacobs Levy Equity Management sold 37,646 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $182K.
- Jacobs Levy Equity Management first reported a position in Stemline Therapeutics, Inc. in Q2 2015 and held it in 12 quarters.
- Jacobs Levy Equity Management's Stemline Therapeutics, Inc. position peaked at $555K in Q3 2016.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2020, filed 17 Aug 2020.